Bringing doctors together

or

A free, private network for verified physicians

Leading voices

Dr. Nneka Ufere

Liver Transplant · MGH

View

Dr. Vinay Jahagirdar

Liver Transplant · Medical College of Virginia

View

Dr. Lauren Feld

Liver Transplant · UMass Memorial

View

Dr. Sonali Paul

Liver Transplant · UCMC

View

Dr. Pierre Gholam

Liver Transplant · CWRU

View

Dr. Elliot Tapper

Liver Transplant · UM

View

Dr. Saurabh Sethi

General GI · Oja Health

View

Dr. Sara Horst

IBD · Vanderbilt

View

Dr. Wendi LeBrett

General GI · ModernGut

View

Dr. Treta Purohit

General GI · Oshi Health

View
  • Discover your community

  • Stay current

  • A profile that represents you

  • Find your people

About RoonPrivacyTerms

    Overview

    Effects of Semaglutide on Muscle Structure and Function in the SLIM LIVER Study.

    Feb 24, 2025DOI: 10.1093/cid/ciae384Clinical Trial, Phase IICID

    Written by: Grace L DitzenbergerJordan E LakeDouglas W KitchAmy KantorRaja MuthupillaiCarlee MoserPablo F Belaunzaran-ZamudioTodd T BrownKathleen CoreyAlan L LandayAnchalee AvihingsanonFred R SattlerKristine M Erlandson

    Find these authors on Roon

    KC
    Dr. Kathleen Corey
    Liver Transplant · PHS

    Summary

    BACKGROUND: Semaglutide is highly effective for decreasing weight. Concomitant loss of muscle mass often accompanies weight loss and may have consequences on muscle function.METHODS: This is a secondary analysis from the SLIM LIVER (Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections, ACTG A5371) study, a single-arm study of semaglutide in people with human immunodeficiency virus (HIV, PWH) with metabolic dysfunction-associated steatotic liver diseases (MASLD). Participants received subcutaneous semaglutide for 24 weeks (titrated to 1 mg/week by week 4). Psoas volume and fat fraction were assessed from liver magnetic resonance imaging, and physical function was assessed by 10-time chair rise test and 4 m gait speed. Mean change from baseline to week 24 was estimated with linear regression modeling.RESULTS: Fifty-one PWH were enrolled (muscle measures n = 46). The mean age was 50 years (standard deviation, 11), body mass index was 35.5 kg/m2 (5.6), 43% were women, 33% Black, and 39% Hispanic/Latino. Psoas muscle volume decreased by 9.3% (95% confidence interval to -5.2; P < .001) over 24 weeks, but psoas muscle fat did not significantly change (-0.42%; 95% CI: -1.00 to .17; P = .16). Chair rise and gait speed showed nonsignificant improvements of 1.27 seconds (95% CI: -2.7 to .10) and 0.05 m/sec (95% CI: -.01 to .10), respectively (both P > .07). The prevalence of slow gait speed (<1 m/sec) decreased from 63% to 46% (P = .029).CONCLUSIONS: In PWH receiving semaglutide for MASLD, despite decreased psoas muscle volume, there was no significant change in physical function, suggesting function was maintained despite significant loss of muscle.CLINICAL TRIALS REGISTRATION: NCT04216589.
    KCDr. Kathleen Corey

    Dr. Kathleen Corey

    Gastroenterology · Hepatology & Liver Transplantation
    Mass General Brigham
    kathleencorey